NCT00843024已完成3 期
TXA107979: A Randomized, Multicenter, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of a Combination Product Containing Sumatriptan and Naproxen Sodium for the Acute Treatment of Migraine in Adolescents
适应症
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 589
- 试验地点
- 1
- 主要终点
- Number of Participants Who Were Pain Free at 2 Hours Post-dose
研究概览
简要总结
This study was designed to determine how well the combination medication, sumatriptan and naproxen sodium, treats migraine headache in adolescents 12-17 years old
详细描述
The purpose of this study is to determine whether the combination product, sumatriptan and naproxen sodium, is effective compared to placebo in the treatment of acute migraine in adolescent subjects 12-17 years old. Subjects will treat two migraine attacks over a ~25 week period.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 12 Years 至 17 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects eligible for enrollment in the study must meet all of the following criteria:
- •Subject is >/=12 years of age and </=17 years of age at the Screening Visit.
- •Subject has migraine with or without aura (ICHD-II criteria, 1.2.1 or 1.1). A history of at least two, but no more than eight attacks per month, for the six months prior to the Screening Visit is required. Attacks should last a minimum of three hours and be associated with moderate-to-severe headache pain.
- •Subject is able to distinguish migraine from other headaches (i.e., tension-type headaches).
- •Male or female subjects. Female subjects are eligible for participation in the study if they are:
- •Females of non-childbearing potential; or
- •Females of childbearing potential, and who have a negative urine pregnancy test at screening, and agree to use one of the GlaxoSmithKline (GSK)-specified highly effective methods for avoiding pregnancy
- •Any subject taking oral contraceptives at enrollment must be on a stable regimen for at least 2 months prior to screening.
- •Subject and subject's parent or legal guardian are able to read and write English or Spanish.
- •Subject is able to read, comprehend, and complete subject diaries.
- •Subject's parent or legal guardian is willing and able to provide Informed Consent prior to subject entry into the study.
- •Subject is willing and able to provide Informed Assent prior to entry into the study (if required).
排除标准
- •Subjects meeting any of the following criteria must not be enrolled in the study:
- •Subject is < 74 pounds (33.3 kg).
- •Subject has ≥15 headache days per month in total (migraine, probable migraine, or tension-type), retinal (ICHD-II 1.4), basilar (ICHD-II 1.2.6), or hemiplegic migraine (ICHD-II 1.2.4), or secondary headaches.
- •Subject, in the investigator's opinion is likely to have unrecognized cardiovascular or cerebrovascular disease.
- •Subject has uncontrolled hypertension at screening or is taking any angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker.
- •Subject has a history of congenital heart disease, cardiac arrhythmias requiring medication, or a history of a clinically significant electrocardiogram abnormality that, in the investigator's opinion, contraindicates participation in this study.
- •Subject has evidence or history of any ischemic vascular diseases including: ischemic heart disease, ischemic abdominal syndromes, peripheral vascular disease, or signs/symptoms consistent with any of the above.
- •Subject has evidence or history of central nervous system pathology including stroke and/or transient ischemic attacks (TIAs), epilepsy or structural brain lesions which lower the convulsive threshold, or has been treated with an antiepileptic drug for seizure control within 5 years prior to screening.
- •Subject has a history of impaired hepatic or renal function that, in the investigator's opinion, contraindicates participation in this study.
- •Subject has hypersensitivity, allergy, intolerance, or contraindication to the use of any triptan, NSAID, or aspirin (including all sumatriptan and naproxen preparations) or has nasal polyps and asthma.
- •Subject has used an ergot medication in the previous three months for migraine prophylaxis or is taking a medication that is not stabilized (i.e., change of dose within the past 2 months) for either chronic or intermittent migraine prophylaxis or for a co-morbid condition that is not stabilized.
- •Subject has a recent history of regular use of opioids or barbiturates for treatment of their migraine headache and/or other non-migraine pain. Regular use is defined as an average of 4 days per month over the last 6 months.
- •Subject has taken, or plans to take, a monoamine oxidase inhibitor (MAOI), including herbal preparations containing St. John's Wort (Hypericum perforatum), anytime within the two weeks prior to screening through two weeks post treatment.
- •Subject has a history of any bleeding disorder or is currently taking any anti-coagulant or any antiplatelet agent.
- •Subject has evidence or history of any gastrointestinal surgery, GI ulceration, or perforation in the past six months, gastrointestinal bleeding in the past year, or evidence or history of inflammatory bowel disease.
- •Subject is pregnant, actively trying to become pregnant, or breast feeding or subject is not willing to have pregnancy test(s).
- •Subject tests positive for illicit substances on toxicology screen, or has evidence of alcohol or substance abuse within the last year, or any concurrent medical or psychiatric condition which, in the investigator's judgment, will likely interfere with the study conduct, subject cooperation, or evaluation and interpretation of the study results, or which otherwise contraindicates participation in this clinical trial.
- •Subject has participated in any investigational drug trial within the previous 4 weeks or plans to participate in another study at any time during this study.
研究组 & 干预措施
Sumatriptan and Naproxen 1
Experimental
Sumatriptan succinate and naproxen sodium combination 10mg/60mg
干预措施: Sumatriptan and Naproxen Sodium (Drug)
Sumatriptan and Naproxen 2
Experimental
Sumatriptan succinate and naproxen sodium combination 30mg/180mg
干预措施: Sumatriptan and Naproxen Sodium (Drug)
Sumatriptan and Naproxen 3
Experimental
Sumatriptan succinate and naproxen sodium combination 85mg/500mg
干预措施: Sumatriptan and Naproxen Sodium (Drug)
Placebo
Placebo Comparator
Placebo to match
干预措施: Placebo (Drug)
结局指标
主要结局
Number of Participants Who Were Pain Free at 2 Hours Post-dose
时间窗: 2 hours after single dose of double-blind treatment (Randomization through Week 13)
Participants were evaluated (self-assessment) for pain intensity by using a 4-point rating scale: 0=none, 1=mild, 2=moderate, and 3=severe. Participants with pain-free response were considered as those who had a reduction in migraine headache pain from moderate (score=2) or severe (score=3) at baseline to none (score=0) post-treatment, without the use of rescue medication (additional medication taken by participants for the treatment of migraine pain or associated symptoms) prior to or at 2 hours post-dose.
次要结局
- Number of Participants Sustained Pain-free From 2-24 Hours(2 to 24 hours after single dose of double-blind treatment (Randomization through Week 13))
- Number of Participants Photophobia-free at 2 Hours Post-dose(2 hours after single dose of double-blind treatment (Randomization through Week 13))
- Number of Participants Phonophobia-free at 2 Hours Post-dose(2 hours after single dose of double-blind treatment (Randomization through Week 13))
- Number of Participants Pain-free at 1 Hour Post-dose(1 hour after single dose of double-blind treatment (Randomization through Week 13))
- Number of Participants Sustained Photophobia-free From 2-24 Hours(2 to 24 hours after single dose of double-blind treatment (Randomization through Week 13))
- Number of Participants Sustained Phonophobia-free From 2-24 Hours(2 to 24 hours after single dose of double-blind treatment (Randomization through Week 13))
- Number of Participants Sustained Nausea-free From 2-24 Hours(2 to 24 hours after single dose of double-blind treatment (Randomization through Week 13))
- Number of Participants Who Used Rescue Medication From 2 to 24 Hours Post Dose(2 to 24 hours after single dose of double-blind treatment (Randomization through Week 13))
- Number of Participants Who Used Their First Dose of Rescue Medication Through the Indicated Time Points(Dosing to 24 hours after single dose of double-blind treatment (Randomization through Week 13))
- Number of Participants Nausea-free at 2 Hours Post-dose(2 hours after single dose of double-blind treatment (Randomization through Week 13))
研究者
研究点 (1)
Loading locations...
相似试验
撤回
3 期
Efficacy and Safety of a Fixed-dose Combination of Naratriptan and Naproxen in Acute Treatment of MigraineHeadacheMigraineNCT01390324Ache Laboratorios Farmaceuticos S.A.
已完成
3 期
A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2)Migraine DisordersNCT00383162GlaxoSmithKline173
已完成
3 期
A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 2 of 2)Migraine DisordersNCT00382993GlaxoSmithKline169
Unknown
不适用
Efficacy of Sumatriptan With Naprosyn in Migraine With AuraMigraine With AuraNCT00893594Dent Neurologic Institute30
已完成
不适用
A Combination Product of Sumatriptan and Naproxen Sodium Versus Single-entity Oral Triptans: An Analysis of Real World DataMigraine DisordersNCT01381523GlaxoSmithKline1